 KMTSJ, Inc.	DEPARTMENT:	Utilization Management
	SUBJECT:	Fecal Transplant
	PRODUCT LINE:	All
	POLICY NUMBER:	UM83
	ORIGINAL POLICY EFFECTIVE DATE:	11/18/2016
	LAST REVISED DATE:	03/15/2018
	LAST REVIEWED DATE:	04/03/2024

SCOPE: To ensure Group Health Cooperative of Eau Claire (the Cooperative) consistently and correctly administers the fecal bacteriotherapy benefit to all members according to their policy.

PROCEDURE:

Prior Authorization Required: YES

All Product Lines:


Fecal microbiota transplant (FMT) has been evaluated as an alternative treatment modality to colectomy in the management of recurrent Clostridium difficile infections (CDI) that is refractory to antibiotic therapy. FMT is currently not routinely performed for indications other than recurrent CDI. More research studies are still needed to determine if fecal transplantation should be performed for other clinical indications. Fecal transplantation for other clinical indications should be considered experimental/investigational. FMT is considered medically necessary for persons with CDI who meet the criteria below:

1. Recurrent infection of C. difficile toxin with the following:
 - a. Must have had at least three episodes of C. difficile infection; **AND**
 - b. Infection must be confirmed by a positive stool test for C. difficile toxin; **AND**
 - c. Current infection has failed to resolve with at least 2 courses of adequate antibiotic therapy (10 or more days of vancomycin at a dose of greater than or equal to 125 mg 4 times per day or 10 or more days of metronidazole at a dose of 500 mg 3 times per day); **AND**
 - d. Member is not immunocompromised; **OR**


2. Moderate or severe CDI that:
 - a. Infection must be confirmed by positive stool test for C. difficile toxin; **AND**
 - b. Current infection has failed to resolve with at least 2 courses of adequate antibiotic therapy (10 or more days of vancomycin at a dose of greater than or equal to 125 mg 4 times per day or 10 or more days of metronidazole at a dose of 500 mg 3 times per day); **AND**
 - c. Member is not immunocompromised

Fecal bacteriotherapy is considered experimental and investigational for all other indications including the following (not an all-inclusive list):

- Crohn's disease
- Idiopathic thrombocytopenic purpura
- Inflammatory bowel diseases
- Insulin resistance
- Irritable bowel syndrome
- Metabolic syndrome

 KMTSJ, Inc.	DEPARTMENT:	Utilization Management
	SUBJECT:	Fecal Transplant
	PRODUCT LINE:	All
	POLICY NUMBER:	UM83
	ORIGINAL POLICY EFFECTIVE DATE:	11/18/2016
	LAST REVISED DATE:	03/15/2018
	LAST REVIEWED DATE:	04/03/2024

Multiple sclerosis
Ulcerative colitis

APPROVED:  DATE: 04/03/2024

REVISION HISTORY:

Rev. Date	Revised By/Title	Summary of Revision
01/17/2018	Michele Bauer, MD	Updated criteria: need to fail 2 courses of abx Rx
03/18/2018	Michele Bauer, MD	Updated criteria. Added criteria number 2
04/10/2019	Michele Bauer, MD, CMO	Reviewed without changes
04/28/2020	Michele Bauer, MD, CMO	Reviewed. No change.
04/28/2021	Michele Bauer, MD, CMO	Reviewed. No changes.
04/13/2022	Michele Bauer, MD, CMO	Reviewed. No changes.
04/04/2023	Michele Bauer, MD, CMO	Reviewed. No changes.
04/03/2024	Michele Bauer, MD, CMO	Reviewed. No changes.